US authorities looking into price fixing in the generics industry are now investigating 16 companies and the price of at least 300 drugs, according to a press report.
Boehringer Ingelheim has said it has axed ex-US development of its biosimilars, focusing instead on getting its Humira near-copy on the US market as soon as possible.
The UK government has reached a new five-year medicines pricing deal with the pharma industry to replace the almost 60-year-old Pharmaceutical Price Regulation Scheme (PPRS).
Spark Therapeutics’ gene therapy for a rare inherited sight disorder, Luxturna has been approved in Europe, but there was still no word on price from marketing partner Novartis.